Dr. Kuriakose will step into the role May 1, according to a March 27 news release. He joins Terns Oncology from Calithera Biosciences, where he served as chief medical officer and led two mid-stage clinical programs.
Dr. Kuriakose also has experience leading the global clinical program at the Cambridge, Mass.-based Novartis Institutes for BioMedical Research and as medical director of Novartis Oncology, where he designed and executed oncology trials.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
